WO1999002564A3 - Ancrod spezifische monoklonale antikörper, antikörperfragmente, deren mischungen oder derivate und deren verwendung - Google Patents

Ancrod spezifische monoklonale antikörper, antikörperfragmente, deren mischungen oder derivate und deren verwendung Download PDF

Info

Publication number
WO1999002564A3
WO1999002564A3 PCT/EP1998/003834 EP9803834W WO9902564A3 WO 1999002564 A3 WO1999002564 A3 WO 1999002564A3 EP 9803834 W EP9803834 W EP 9803834W WO 9902564 A3 WO9902564 A3 WO 9902564A3
Authority
WO
WIPO (PCT)
Prior art keywords
mixtures
derivatives
antibody fragments
ancrod
monoclonal antibodies
Prior art date
Application number
PCT/EP1998/003834
Other languages
English (en)
French (fr)
Other versions
WO1999002564A2 (de
Inventor
Thomas Subkowski
Wilfried Hornberger
Original Assignee
Basf Ag
Thomas Subkowski
Wilfried Hornberger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU85406/98A priority Critical patent/AU748841B2/en
Priority to BR9810574-4A priority patent/BR9810574A/pt
Priority to KR1020007000207A priority patent/KR20010021649A/ko
Priority to CA002295218A priority patent/CA2295218A1/en
Priority to IL13322498A priority patent/IL133224A0/xx
Priority to HU0003029A priority patent/HU225784B1/hu
Application filed by Basf Ag, Thomas Subkowski, Wilfried Hornberger filed Critical Basf Ag
Priority to EP98936383A priority patent/EP1000087A2/de
Priority to US09/446,983 priority patent/US6365155B1/en
Priority to JP50805199A priority patent/JP2002511880A/ja
Publication of WO1999002564A2 publication Critical patent/WO1999002564A2/de
Publication of WO1999002564A3 publication Critical patent/WO1999002564A3/de
Priority to NO20000079A priority patent/NO20000079L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Die Erfindung betrifft Ancrod spezifische monoklonale Antikörper, Antikörperfragmente, deren Mischungen oder Derivate und deren Verwendung in pharmazeutischen Zubereitungen oder in der Diagnostik. Weiterhin betrifft die Erfindung Zellen, die diese Antikörper, Antikörperfragmente, deren Mischungen oder Derivate exprimieren.
PCT/EP1998/003834 1997-07-10 1998-06-23 Ancrod spezifische monoklonale antikörper, antikörperfragmente, deren mischungen oder derivate und deren verwendung WO1999002564A2 (de)

Priority Applications (10)

Application Number Priority Date Filing Date Title
BR9810574-4A BR9810574A (pt) 1997-07-10 1998-06-23 Anticorpo monoclonal, fragmento de anticorpo, mistura ou derivado destes, uso dos mesmos, célula, e, preparação farmacêutica.
KR1020007000207A KR20010021649A (ko) 1997-07-10 1998-06-23 앤크로드 특이적 모노클로날 항체, 항체 단편, 그의혼합물 또는 유도체 및 그의 용도
CA002295218A CA2295218A1 (en) 1997-07-10 1998-06-23 Ancrod specific monoclonal antibodies, antibody fragments, mixtures or derivatives thereof and use of the same
IL13322498A IL133224A0 (en) 1997-07-10 1998-06-23 Ancrod specific monoclonal antibodies antibody fragments mixtures or derivatives thereof and use of the same
HU0003029A HU225784B1 (en) 1997-07-10 1998-06-23 Ancrod specific monoclonal antibodies, antibody fragments and mixtures thereof, pharmaceutical preparations containing them and use of the same
AU85406/98A AU748841B2 (en) 1997-07-10 1998-06-23 Ancrod specific monoclonal antibodies, antibody fragments, mixtures or derivatives thereof and use of the same
EP98936383A EP1000087A2 (de) 1997-07-10 1998-06-23 Ancrod spezifische monoklonale antikörper, antikörperfragmente, deren mischungen oder derivate und deren verwendung
US09/446,983 US6365155B1 (en) 1997-07-10 1998-06-23 Ancrod-specific monoclonal antibodies, antibody fragments, mixtures or derivatives thereof and use of the same
JP50805199A JP2002511880A (ja) 1997-07-10 1998-06-23 アンクロッド−特異的モノクローナル抗体、抗体フラグメント、その混合物または誘導体およびそれらの使用
NO20000079A NO20000079L (no) 1997-07-10 2000-01-07 Ancrod spesifikke monoklonale antistoff, antistoff- fragmenter, blandinger, derivater og anvendelse derav

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19729544.4 1997-07-10
DE19729544A DE19729544A1 (de) 1997-07-10 1997-07-10 Ancrod spezifische monoklonale Antikörper, Antikörperfragmente, deren Mischung oder Derivate und deren Verwendung

Publications (2)

Publication Number Publication Date
WO1999002564A2 WO1999002564A2 (de) 1999-01-21
WO1999002564A3 true WO1999002564A3 (de) 1999-04-01

Family

ID=7835268

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/003834 WO1999002564A2 (de) 1997-07-10 1998-06-23 Ancrod spezifische monoklonale antikörper, antikörperfragmente, deren mischungen oder derivate und deren verwendung

Country Status (14)

Country Link
US (1) US6365155B1 (de)
EP (1) EP1000087A2 (de)
JP (1) JP2002511880A (de)
KR (1) KR20010021649A (de)
CN (1) CN1262690A (de)
AU (1) AU748841B2 (de)
BR (1) BR9810574A (de)
CA (1) CA2295218A1 (de)
CZ (1) CZ297216B6 (de)
DE (1) DE19729544A1 (de)
IL (1) IL133224A0 (de)
NO (1) NO20000079L (de)
WO (1) WO1999002564A2 (de)
ZA (1) ZA986064B (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI513466B (zh) * 2010-01-20 2015-12-21 Boehringer Ingelheim Int 抗凝血劑解毒劑

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006362A1 (de) * 1988-12-10 1990-06-14 Basf Aktiengesellschaft Ancrod-proteine, ihre herstellung und verwendung
EP0395375A1 (de) * 1989-04-26 1990-10-31 Knoll Ag Für Ancrod-ähnliche Polypeptide kodierende DNA-Sequenzen und deren Expressionsprodukte enthaltende Zusammensetzungen
EP0556906A1 (de) * 1992-02-17 1993-08-25 Akzo Nobel N.V. Kalibrator und Verwendung davon in einer Immuntest
EP0592903A2 (de) * 1992-10-14 1994-04-20 Basf Corporation Verwendung von Ancrod zur Herstellung von Medikamenten zur Behandlung von Restenosis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006362A1 (de) * 1988-12-10 1990-06-14 Basf Aktiengesellschaft Ancrod-proteine, ihre herstellung und verwendung
EP0395375A1 (de) * 1989-04-26 1990-10-31 Knoll Ag Für Ancrod-ähnliche Polypeptide kodierende DNA-Sequenzen und deren Expressionsprodukte enthaltende Zusammensetzungen
EP0556906A1 (de) * 1992-02-17 1993-08-25 Akzo Nobel N.V. Kalibrator und Verwendung davon in einer Immuntest
EP0592903A2 (de) * 1992-10-14 1994-04-20 Basf Corporation Verwendung von Ancrod zur Herstellung von Medikamenten zur Behandlung von Restenosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
W. BURKHART ET AL.: "Amino acid sequence determination of Ancrod, the thrombin-like alpha-fibrinogenase from the venom of Agkistrodon rhodostoma.", FEBS LETTERS, vol. 297, no. 3, February 1992 (1992-02-01), Amsterdam, die Niederlande, pages 297 - 301, XP002090091 *

Also Published As

Publication number Publication date
CZ297216B6 (cs) 2006-10-11
JP2002511880A (ja) 2002-04-16
BR9810574A (pt) 2000-09-19
NO20000079D0 (no) 2000-01-07
AU748841B2 (en) 2002-06-13
CZ200057A3 (cs) 2000-05-17
KR20010021649A (ko) 2001-03-15
US6365155B1 (en) 2002-04-02
DE19729544A1 (de) 1999-01-14
EP1000087A2 (de) 2000-05-17
NO20000079L (no) 2000-03-07
IL133224A0 (en) 2001-03-19
CA2295218A1 (en) 1999-01-21
ZA986064B (en) 2000-01-10
CN1262690A (zh) 2000-08-09
WO1999002564A2 (de) 1999-01-21
AU8540698A (en) 1999-02-08

Similar Documents

Publication Publication Date Title
AU1332099A (en) Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use
AU735411C (en) Stable lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies
WO2002002783A3 (en) Expression vectors
WO1997008318A3 (en) Compounds and methods for treatment and diagnosis of prostate cancer
AU3667399A (en) Monoclonal antibodies specific for anthrax spores and peptides derived from the antibodies thereof
WO1996027665A3 (en) Neuron-restrictive silencer factor proteins
HUP9702359A3 (en) Monoclonal antibody, method of preparing a monoclonal antibody, and pharmaceutical composition and a diagnostic reagent comprising the monoclonal antibody
WO1999065947A3 (fr) Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations
ZA976967B (en) Device and process for separating magnetic materials from pharmaceutical preparations, their starting or intermediate products, as well as agents that are produced with the of said device.
WO2001012660A3 (en) HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS
WO1998057983A3 (en) Mammalian neuro-growth factor like protein
TR200102877T2 (tr) İmmünoglobulinin kendi yüksek afinite reseptörüne bağlanmasını inhibe eden antikorlara karşı anti-idiotipik antikorlar.
WO1997029199A3 (en) Prostate specific antigen peptides and uses thereof
WO2001002563A3 (en) HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS
AU2547995A (en) Monoclonal antibody specific for vascular endothelial cell antigen endoglyx-1, the antigen itself, and uses thereof
WO2000018909A3 (en) NUCLEIC ACIDS AND PROTEINS FROM $i(CENARCHAEUM SYMBIOSUM)
WO1999002564A3 (de) Ancrod spezifische monoklonale antikörper, antikörperfragmente, deren mischungen oder derivate und deren verwendung
AU5971598A (en) Novel antibody, renin-active substance containing the same and prorenin assay reagent using the same
AU7165891A (en) Tumor-specific, cell surface-binding monoclonal antibodies
AU3257399A (en) Monoclonal antibodies esm-1 protein specific, and use of said antibodies for detecting esm-1 protein
AU7128098A (en) Methods of obtaining antigens specific for fungi, antibodies for such antigens, and diagnosis of disease using such antigens and/or antibodies
AU7478098A (en) Methods of treatment using nbs-1, antibodies and proteins thereto, and uses of the antibodies
ZA984100B (en) Process for the detection of HIV antibodies and antigens used in it.
WO2001004297A3 (en) Human proteins having hydrophobic domains and dnas encoding these proteins
HUP0003029A3 (en) Ancrod specific monoclonal antibodies, antibody fragments, mixtures or derivatives thereof and use of the same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 133224

Country of ref document: IL

Ref document number: 98807040.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AU BG BR BY CA CN CZ GE HU ID IL JP KR KZ LT LV MX NO NZ PL RO RU SG SI SK TR UA US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AU BG BR BY CA CN CZ GE HU ID IL JP KR KZ LT LV MX NO NZ PL RO RU SG SI SK TR UA US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1998936383

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/011382

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 09446983

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2295218

Country of ref document: CA

Ref document number: 2295218

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV2000-57

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1020007000207

Country of ref document: KR

Ref document number: 85406/98

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1998936383

Country of ref document: EP

Ref document number: PV2000-57

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020007000207

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 85406/98

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1020007000207

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1998936383

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: PV2000-57

Country of ref document: CZ